CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
Minoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in Europe almost two years after its approval in the US. ...
July 24, 2026 09:23 AM EDT Pharma CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa Anna Brown News Reporter Minoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that